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Homeostasis of serotonergic transmission critically depends on the rate of serotonin reuptake via its plasma membrane transporter
(SERT). SERT activity is tightly regulated by multiple mechanisms, including physical association with intracellular proteins and post-
translational modifications, such as phosphorylation, but these mechanisms remain partially understood. Here, we show that SERT
C-terminal domain recruits both the catalytic and regulatory subunits of the Ca2-activated protein phosphatase calcineurin (CaN) and
that thephysical associationof SERTwithCaN ispromotedbyCaNactivity. Coexpressionof constitutively activeCaNwithSERT increases
SERT cell surface expression and 5-HT uptake in HEK-293 cells. It also prevents the reduction of 5-HT uptake induced by an acute
treatment of cells with the protein kinase C activator -PMA and concomitantly decreases PMA-elicited SERT phosphorylation. In
addition, constitutive activation of CaN in vivo favors 5-HT uptake in the adult mouse brain, whereas CaN inhibition reduces cerebral
5-HT uptake. Constitutive activation of CaN also decreases immobility in the forced swim test, indicative of an antidepressant-like effect
of CaN. These results identify CaN as an important regulator of SERT activity in the adult brain and provide a novel molecular substrate
of clinical interest for the understanding of increased risk of mood disorders in transplanted patients treated with immunosuppressive
CaN inhibitors.
Introduction
Homeostasis of serotonergic transmission critically depends on
serotonin (5-HT) reuptake into presynaptic neurons via its
plasmamembrane transporter SERT, amember of theNa/Cl-
dependent transporter family (SLC6) (Torres et al., 2003; Mur-
phy and Lesch, 2008). SERT is of major pharmacological and
clinical interest as it represents the primary target of several
widely prescribed antidepressants, such as selective serotonin re-
uptake inhibitors (SSRIs) (Jayanthi and Ramamoorthy, 2005;
White et al., 2005; Millan, 2006). Moreover, alteration of SERT
functional status has been associated with numerous psychiatric
disorders, including anxiety and depression (Torres et al., 2003;
Murphy and Lesch, 2008). Characterizing the cellular mecha-
nisms that regulate SERT-mediated 5-HT clearance may thus
improve our understanding of these disorders and suggest new
strategies for therapeutic intervention.
Increasing evidence indicates that multiple regulatory mech-
anisms control SERT plasmamembrane expression and catalytic
activity. These include a complex combination of phosphoryla-
tion events on SERT Ser, Thr, and Tyr residues and SERT associ-
ation with accessory/scaffolding proteins (Steiner et al., 2008;
Zhong et al., 2012). Many SERT partners have been identified by
means of two-hybrid screens and/or coimmunoprecipitation, of-
ten based on their previously described interactions with other
SLC6 family transporters (Bauman et al., 2000; Haase et al., 2001;
Jess et al., 2002; Carneiro and Blakely, 2006; Mu¨ller et al., 2006;
Ahmed et al., 2008; Carneiro et al., 2008; Steiner et al., 2009).
Proteomics strategies have also been successfully used to identify
proteins interacting with SERT C terminus, in line with the im-
portance of this domain in the localization and activity of SERT
(Larsen et al., 2006). They revealed an association of SERT with
the intermediate filament protein vimentin in platelets, which
controls the cellular distribution of SERT (Ahmed et al., 2009).
We likewise demonstrated that the extreme C terminus of SERT
(15 C-terminal amino acids) recruits in brain two PDZ proteins,
neuronal nitric oxide synthase (nNOS) and channel interacting
PDZ protein, and two proteins of the coat complex II (COPII),
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Sec23A and Sec24C (Chanrion et al., 2007). Further studies
showed that SERT/nNOS interaction sequesters SERT in intra-
cellular compartments whereas SERT association with Sec24C is
required for its export from the endoplasmic reticulum (Chan-
rion et al., 2007; Sucic et al., 2011), underscoring the power of
proteomics approaches to identify novel SERT regulatory
mechanisms.
Here, we have used a complementary strategy using the entire
C terminus of SERT as bait to identify additional brain partners
of SERT recruited by interactionmotifs located upstream to its 15
C-terminal amino acids.We found that SERT interacts with both
the catalytic and regulatory subunits of calcineurin (CaN), a
Ca2-calmodulin-activated protein phosphatase enriched in
brain, which has been involved in synaptic plasticity and in the
mechanism of action of SSRI antidepressants (Mansuy, 2003;
Crozatier et al., 2007; Baumga¨rtel and Mansuy, 2012). These ex-
periments were complemented by a series of in vitro and in vivo
studies to determine the impact of CaN activity and CaN/SERT
interaction upon 5-HT transport via SERT.We also explored the
effect of cerebral CaN activation in a behavioral paradigm rele-
vant for antidepressant action.
Materials andMethods
Materials. [ 3H]-5-HT creatine sulfate (95 Ci/mmol), [ 3H]-citalopram
(82 Ci/mmol), [ 3H]-dihydroxyphenylethylamine dopamine (38.7 Ci/
mmol), and [3H]-norepinephrine hydrochloride (14.9 Ci/mmol) were
purchased from PerkinElmer. Oligonucleotides were from Eurogentec.
The cell culture media and antibiotics were from Invitrogen. All chemi-
cals were from Sigma-Aldrich.
Plasmids encoding CA-CaNA (pCMV-Flag/CA-CaNA) and PD-
CaNA (pCMV-Flag/PD-CaNA) were kindly provided by Dr. Jean-
Antoine Girault (Institut du Fer a` Moulin, Paris). The CA-CaNA
(constitutively active calcineurin Amutant) construct bears a deletion of
the auto-inhibitory domain (398–521). The PD-CaNA (phosphatase-
dead calcineurin Amutant) construct bears the same deletion (398–521)
and a mutation in the catalytic domain (D130N). The plasmid encoding
CaNB (pCMV-CaNB-Flag) was provided by Dr. Alain Lilienbaum (Uni-
versity Paris-Diderot). The plasmids encoding YFP-tagged human SERT
(pEYFP/SERT), dopamine transporter (DAT, pEYFP/DAT), andnorepi-
nephrine transporter (NET, pEYFP/NET) were kindly provided by Dr.
Michael Freissmuth (Medical University of Vienna). The pEYFP/
SERTCaN construct was obtained by mutating the CaN binding site in
the human SERT sequence ( 596RLIIT600 to 596ALAAA600).
Themousemonoclonal anti-GFP antibody (mixture of clones 7.1 and
13.1) was from Roche Diagnostics, the rabbit polyclonal anti-GFP anti-
body from Invitrogen, the rabbit polyclonal anti-SERT antibody from
ImmunoStar, the rabbit polyclonal anti-CaNA and CaNB antibody from
Millipore Bioscience Research Reagents, the rabbit polyclonal anti-
CaNA antibody from Millipore, the mouse monoclonal anti-CaNA an-
tibody and the polyclonal anti-Flag antibody from Sigma-Aldrich, and
the rabbit anti-GAPDH antibody from Santa Cruz Biotechnology.
Animals. CN279 (with inducible expression of a constitutively active
CaN in forebrain neurons) and 211 (with inducible expression of CaN
auto-inhibitory domain (211) in forebrain neurons)micewere described
previously (Mansuy et al., 1998; Malleret et al., 2001). In both models,
transgene expression was induced by doxycycline (dox) treatment (6 mg
of dox for 100 g of wet food, administered daily for 12 d). Control mice
were littermates of double transgenic mice (CN279 or 211) that carried
either no transgene or either one of each of the transgenes (rtTA2, tetO-
CAM-AI, or tetO-211 transgenes). They were similarly treated with
dox, as previously described (Mansuy et al., 1998; Malleret et al., 2001).
All mice have the same genetic background (C57BL/6J) and were back-
crossed15 times.
Mice were maintained in standard laboratory conditions (12 h light/
dark cycle with light on at 07:30 A.M.; room temperature 21°C), with
food and water ad libitum. Experiments conformed to European ethics
standards (86/609-EEC), to decrees of the French National Ethics Com-
mittee (87/848) and to guidelines and regulations of the Cantonal Vet-
erinary Office, Zu¨rich, for the care and use of laboratory animals.
Cell culture and transfection.HEK-293 cells were grown at 37°C in a 5%
CO2 humidified atmosphere, in DMEM supplemented with 10% dia-
lyzed FCS. Transfectionwas performed by electroporation using the Bio-
Rad Gene Pulser X cell. Immunocytofluorescence experiments indicated
that50% of the cells were transfected with SERT, DAT, NET, and CaN
constructs.
For experiments using siRNAs, cells were transfected in suspension
with 200 nM of either CaNA Predesigned Mission siRNA (Sigma-
Aldrich) orUniversal Negative Control siRNA (Sigma-Aldrich) and 1g
YFP-SERT plasmid using Lipofectamine (Invitrogen). Cells were used
40 h after transfection. Downregulation of CaNA expression was ana-
lyzed by Western blotting using the polyclonal anti-CaNA antibody.
Primary cultures of mesencephalic neurons were prepared from 13-d-
old mouse embryos, as previously described (Chamak and Prochiantz,
1989). Briefly, cells were plated on polyornithine-coated 12-well culture
dishes (1 106 cells/well) in serum-free medium consisting of DMEM/
F12 (1:1), 33 mM D-glucose, 2 mM L-glutamine, 13 mM NaHCO3, 5 mM
HEPES, pH 7.4, and supplemented with 10% of hormone and salt mix-
ture (25 g/ml insulin, 100 g/ml transferrin, 60 M putrescine, 20 nM
progesterone, and 30 nM sodium selenite). Cultures were maintained at
37°C in a humidified atmosphere in 5% CO2 and used 8 d after seeding.
GST pull-down assays. A PCR fragment corresponding to the entire
SERT C-terminal domain (RLIITPGTFKERIIKSITPETPTEIPCGDIRL-
NAV, SERT-Ct) was subcloned into the pGEX-3X bacterial expression
vector (GE Healthcare). A total of 50 g of GST or GST-SERT-Ct fusion
proteins (produced in BL-21 cells) was immobilized onto glutathione
Sepharose beads (GE Healthcare) and incubated overnight at 4°C with 1
mg (for Western blotting) or 10 mg (for proteomics analysis) of mice
brain proteins solubilized in 50 mM Tris-HCl, pH 7.4, 0.5 mM EDTA,
1.3% CHAPS, and a protease inhibitor mixture (Roche). Samples were
washed four timeswith 50mMTris-HCl, pH7.4, 0.5MNaCl, and retained
proteins were separated by SDS-PAGE or 2-D electrophoresis, as previ-
ously described (Chanrion et al., 2007).
Protein identification by mass spectrometry. Protein identification was
performed by mass spectrometry using two different procedures. In the
first one, protein spots detected on 2-D gels obtained from pull-downs
with GST-SERT-Ct and absent in gels from control pull-downs were
excised, digested in gel with trypsin (Gold; Promega), and peptides were
analyzed using an Ultraflex MALDI-TOF mass spectrometer (Bruker
Daltonik). Analyses were performed in reflectron mode with an acceler-
ating voltage of 25 kV and a delayed extraction of 50 ns. The spectra were
analyzed using the FlexAnalysis software (version 2.4, Bruker Daltonik),
and autoproteolysis products of trypsin (molecular weights, 842.51,
1045.56, 2211.10, and 2383.90) were used as internal calibrates. Identifi-
cation of proteins was performed using the Mascot software (version
2.0.04, Matrix Science; http://www.matrixscience.com/) against the
mouse entries of Sprot or Trembl databases (downloaded on 2005-05-
15). The following parameters were used for database interrogation:
mass tolerance of 50 ppm (even if the mass accuracy of our analyses was
usually better than 20 ppm); fixed chemical modification, carbamidom-
ethylation of cysteines; variable chemical modification, oxidation of me-
thionines; and one missed cleavage accepted and significance threshold
p 0.05. In the second procedure, pulled-down proteins were separated
by SDS-PAGE and systematically identified by nano-flow liquid chro-
matography coupled to Fourier transform tandemmass spectrometry
(nano-LC-FT-MS/MS) using a LTQ-Orbitrap-XL (Thermo Fisher Sci-
entific), as previously described (Meffre et al., 2012). MS/MS spectra
were searched against the mouse Complete Proteome Set database
(downloaded on 2012-07-15) by usingMascot (version 2.3) with trypsin
enzyme specificity and up to two trypsin missed cleavages. Methionine
oxidation was set as variable modification for searches. A peptide mass
tolerance of 7 ppm and a fragmentmass tolerance of 0.5 Da were allowed
for identification. Peptide validation and peptide counting were per-
formed using theMyProMS version 2.3Web server (Poullet et al., 2007),
to obtain a false discovery rate1%.Only proteins identifiedwith two or
more peptides by MS/MS were considered as potential SERT partners.
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For each procedure, the experiments were repeated three times to assess
reproducibility.
Analysis of SERT phosphorylation status by MS/MS. YFP-SERT ex-
pressed in HEK-293 cells was immunoprecipitated using the GFP-Trap
kit (Chromotek). Immunoprecipitated proteins were separated by SDS-
PAGE, and the bands corresponding to SERTwere digested with trypsin.
Peptides were analyzed by nano-LC-FT-MS/MS and searched against the
human Complete Proteome Set database (downloaded on 2012-02-22)
as described above, with phosphorylation of Ser, Thr, and Tyr as variable
modifications. Ion signals corresponding to phosphorylated peptides
were quantified from their extracted ion chromatograms manually ex-
tracted using Qual browser version 12.1 (Thermo Fisher Scientific) with
a tolerance of 5 ppm formass deviation and normalized to signals of their
nonphosphorylated counterparts.
Coimmunoprecipitation.CHAPS-solubilized proteins frommice brain
(1 mg of protein per condition) were incubated overnight at 4°C with 10
l of anti-SERT antiserum or 10 l of rabbit nonimmune serum. Solu-
bilized proteins from transfected HEK-293 cells (1 mg) were incubated
with 1 g of anti-Flag antibody or control goat IgG. Immunocomplexes
were captured by incubation with protein A-Sepharose beads (GE
Healthcare) for 1 h at 4°C. Beads were washed three times with 50 mM
Tris-HCl, pH 7.4, and immunoprecipitated proteins were analyzed by
Western blotting.
Western blotting. Proteins resolved on 10% or 13.5% SDS-PAGE were
transferred electrophoretically onto nitrocellulose membranes (Hy-
bond-C; GE Healthcare). Membranes were incubated in blocking buffer
(Tris-HCl 50 mM, pH 7.5, NaCl 200 mM, Tween 20, 0.1% and 5%
skimmed dried milk) for 1 h at room temperature, and overnight with
primary antibodies (rabbit anti-GFP 1/1000;mouse anti-GFP 1/500; rab-
bit anti-Flag 1/1000; rabbit anti-CaN A and B 1/1000; rabbit anti-CaNA
1/1000; mouse anti-CaNA 1/2000; rabbit anti-GAPDH1/1000) in block-
ing buffer at 4°C. They were washed three times with blocking buffer and
incubated with horseradish peroxidase-conjugated anti-rabbit or anti-
mouse antibodies (1:5000, GE Healthcare) for 1 h at room temperature.
Immunoreactivity was detected with an enhanced chemiluminescence
method (ECL detection reagent, GE Healthcare).
Luciferase assay. HEK-293 cells electroporated with the NFAT-Luc
plasmid in the presence or absence of CaN constructs were lysedwithGlo
Lysis Buffer (Promega), and luciferase activity in cell lysates was deter-
mined using the Bright-Glo Luciferase Assay (Promega), according to
the manufacturer’s instructions.
5-HT, dopamine, and norepinephrine uptake assays.HEK-293 cells grown
in 96-well culture dishes were washed in HEPES buffer (NaCl 150mM, KCl
4.2mM,CaCl20.9mM,MgSO40.5mM,glucose5mM,HEPES10mM,pH7.4)
and incubated for 10 min at 37°C in HEPES buffer containing 100M par-
gylineand100Mascorbicacid.5-HTuptakewas initiatedby theadditionof
[3H]-5-HT (20 nM) and increasing concentrations of cold 5-HT ranging
from0.1 to 50M (for 10min at 37°C) and terminated by threewasheswith
ice-cold HEPES buffer containing 10M of fluoxetine, followed by cell lysis
in 1% SDS. Nonspecific 5-HT uptake was determined in the presence of 10
M of fluoxetine. For 5-HT uptake into cultured mesencephalon neurons,
cultures were plated in 12-well culture dishes, pretreated as indicated above,
and uptake was initiated by the addition of 100 nM [3H]-5-HT.Nonspecific
5-HTuptakewasdetermined in thepresence of 50nM fluoxetine. The radio-
activity incorporated into cells was determined by scintillation counting.
Dopamine and norepinephrine uptake was performed in HEK-293
cells using a procedure similar to that used for [ 3H]-5-HT uptake. Up-
take was initiated by the addition of [ 3H]-dopamine (20 nM) or [ 3H]-
norepinephrine hydrochloride (20 nM) and increasing concentrations of
cold dopamine or norepinephrine ranging from 0.5 to 30 M. Determi-
nation of nonspecific uptake was performed in the presence of 5 M of
GBR12909 and 10 M of imipramine, respectively.
Biotinylation assay. Biotinylation was performed in transfected HEK-
293 cells using the Cell Surface Isolation kit (Pierce), according to the
manufacturer’s instructions. Briefly, 48 h after transfection, cells were
washed in ice-cold PBS, pH 8.0, and incubated with 1 mg/ml of sulfo-
NHS-SS-biotin under gentle agitation for 30 min at 4°C. After washing,
cells were scraped off in 1 ml of lysis buffer and lysates were spun at
8000 g for 10 min. Clarified cell lysates were then incubated overnight
at 4°C with 200 l of neutravidin-agarose beads. The beads were washed
three times in lysis buffer and once in Tris-HCl 50mM, pH7.4, and proteins
retained on the beads were eluted with 100 l of SDS sampling buffer. The
amount of SERT was analyzed in lysates and eluates (biotinylated fraction)
byWestern blotting, using the monoclonal anti-GFP antibody.
Preparation of synaptosomes and synaptosomal 5-HT uptake. Synapto-
somes were prepared according to the method described by Kolomi-
ytseva et al. (2008). Briefly, brains from CN279 or 211 mice and their
corresponding controls were gently homogenized with a glass-Teflon
homogenizer in 10 volumes of ice-cold buffer containing 50 mM Tris-
HCl, pH 7.4, 0.32 M sucrose, and the protease inhibitor mixture (Roche).
The homogenates were centrifuged at 1500 g for 10min at 4°C. Super-
natants were then centrifuged at 9000  g for 20 min. The pellets were
resuspended in 0.32 M HEPES buffered, pH 7.4, sucrose solution, and
layered over 0.8MHEPES-buffered sucrose solution. After centrifugation
at 9000  g for 25 min, the synaptosomal fraction in the 0.8 M sucrose
layer was diluted to obtain a final 0.32 M sucrose solution and centrifuged
at 9500 g for 20 min. The final pellet (purified synaptosomal fraction)
was gently resuspended inKrebs-Ringer bicarbonatemediumcontaining
150 mM NaCl, 4.2 mM KCl, 0.9 mM CaCl2, 0.5 mM MgSO4, 25 mM
NaHCO3, 10 mMHEPES, pH 7.4, 5 mM glucose, and protease inhibitors,
Figure 1. SERT C terminus interacts with the catalytic and regulatory subunits of calcineurin. A,
CHAPS-solubilizedprotein extracts frommicebrain (10mgofprotein)were incubatedwith50gof
either GST fused to the SERT C-terminal domain (SERT-Ct) or GST alone (Control), immobilized on
gluthatione-Sepharose beads. Proteins retained by affinity were resolved onto 2-D gels. Areas of
silver-stainedgels representativeof threeexperimentsperformed independentlyand includingspots
corresponding to CaNA and CaNB (indicated by arrows) are represented.B, Protein extracts (1mg of
protein)were pulled downwith the indicated GST fusion proteins and analyzed byWestern blotting
with the polyclonal anti-CaN antibody, which recognizes both CaNA and CaNB. C, Protein extracts (1
mg of protein) were immunoprecipitated (IP) with the polyclonal anti-SERT antibody or with rabbit
IgG,andimmunoprecipitateswereanalyzedbyWesternblottingwiththemouseanti-CaNAantibody.
B, C, Data are representative of three independent experiments. Inputs represent 2% of the total
protein amount used for pull-downs or immunoprecipitations.
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and saturated with 95% air/5% CO2. Protein concentration was deter-
mined using the bicinchoninic acid method.
Synaptosomes (0.5 mg per assay) were preincubated with pargyline
(100M) and ascorbic acid (100M) in 0.5ml of Krebs-Ringer bicarbon-
ate buffer for 10 min at 37°C. 5-HT transport assays (10 min at 37°C)
were initiated by the addition of [ 3H]-5-HT (20 nM) and increasing
concentrations of cold 5-HT ranging from 0.05 to 2 M, and terminated
by filtering the samples through 0.3% polyethylenimine-coated glass fi-
ber filters (Whatman GF/C) by using a Brandel cell harvester. Nonspe-
cific [ 3H]-5-HT uptake was determined in the presence of 10 M of
fluoxetine.
[3H]-Citalopram binding. Plasma membrane-enriched fractions
(O’Malley et al., 2003) from brains ofCN279 or 211mice or corresponding
control mice were incubated with increasing concentrations of [ 3H]-
citalopram ranging from 0.125 to 20 nM for 2 h at 25°C in 500l of binding
buffer containing 50 mM Tris-HCl, pH 7.4, 120 mM NaCl, and 5 mM KCl.
Assays were terminated by rapid filtration of the samples through 0.3%
polyethylenimine-coatedglass fiber filters (WhatmanGF/C)using theBran-
del cell harvester. Nonspecific binding was determined in the presence of 10
M fluoxetine.
Behavioral tests. Behavioral tests were performed by an experimenter
blinded to genotype and treatment. The Porsolt Forced Swim Test (FST)
Table 1. Identification of Calcineurin subunits by MALDI-TOFmass spectrometrya
Peptide Start End M/z (Obs) Mr (Exp) Mr (Calc) 
Missed
cleavage Sequence Modification
CaNA (isoform): 11 peptides; protein score: 132; protein
mass: 59,291 Da; peptide coverage: 25%
1 143 148 762.49 761.4786 761.4799 0.001 0 K.TLFLLR
2 20 28 1007.55 1006.5437 1006.5348 0.009 0 K.AVPFPPSHR
3 64 73 1072.65 1071.6405 1071.6288 0.012 0 R.IITEGASILR
4 280 289 1117.55 1116.5398 1116.4948 0.045 0 R.AHEAQDAGYR
5 324 332 1152.55 1151.5477 1151.5393 0.008 0 K.YENNVMNIR
6 33 42 1176.58 1175.5759 1175.557 0.019 0 K.EVFDNDGKPR
7 101 112 1247.64 1246.6361 1246.6305 0.006 0 K.LFEVGGSPANTR
8 113 122 1260.64 1259.6346 1259.6186 0.016 0 R.YLFLGDYVDR
9 244 254 1369.66 1368.6549 1368.6534 0.002 0 K.TQEHFTHNTVR
10 488 501 1489.75 1488.7407 1488.6878 0.053 0 R.DAMPSDANLNSINK
11 425 441 1571.89 1570.8787 1570.8388 0.040 0 K.GLTPTGMLPSGVLSGGK Oxidation (M)
CaNB (isoform 1): 5 peptides; protein score: 56; protein
mass: 19,244 Da; peptide coverage: 35%
1 117 124 906.43 905.42 905.45 0.02 0 K.MMVGNNLK
2 125 134 1187.65 1186.65 1186.62 0.03 0 K.DTQLQQIVDK
3 135 146 1274.67 1273.66 1273.63 0.04 1 K.TIINADKDGDGR
4 73 84 1369.73 1368.72 1368.69 0.03 0 K.EFIEGVSQFSVK
5 57 72 1783.86 1782.85 1782.83 0.02 0 R.VIDIFDTDGNGEVDFK
aThe lists of peptidesmatchingwith the CaNA (isoform) and CaNB (isoform 1) sequences are shown. For each peptide identified, the position in protein sequence, experimental and calculatedmasses, number of trypsinmissed cleavage,
and sequence are indicated.
Table 2. Protein identification by LC-MS/MSa
Peptide Start End Score M/z (Obs) Mr (Exp) Mr (Calc) Missed cleavage Sequence Modification
CaNA (isoform): 5 peptides; protein score:
98; protein mass: 59,291 Da; peptide
coverage: 15%
1 56 63 34.2 458.7583 915.5021 915.5025 0 R.LEESVALR
2 155 163 23.9 593.2999 1184.5853 1184.5866 0 R.HLTEYFTFK
3 101 112 56.0 624.3219 1246.6292 1246.6306 0 K.LFEVGGSPANTR
4 113 122 29.6 630.8168 1259.6191 1259.6186 0 R.YLFLGDYVDR
5 425 441 65.0 794.4231 1586.8317 1586.8338 0 K.GLTPTGMLPSGVLSGGK Oxidation (M)
CaNA (isoform): 4 peptides; protein score:
63; protein mass: 59,721 Da; peptide
coverage: 11%
1 164 172 23.9 593.2999 1184.5853 1184.5866 0 R.HLTEYFTFK
2 110 121 56.0 624.3219 1246.6292 1246.6306 0 K.LFEVGGSPANTR
3 122 131 29.6 630.8168 1259.6191 1259.6186 0 R.YLFLGDYVDR
4 147 157 29.7 668.4056 1334.7966 1334.7962 0 K.ILYPSTLFLLR
CaNB (isoform 1): 2 peptides; protein score:
24; protein mass: 19,402 Da; peptide
coverage: 11%
1 29 57 18.1 1101.5567 3301.6482 3301.65 1 K.KLDLDNSGSLSVEEFMSLPELQQNPLVQR Oxidation (M)
2b 148 165 24.2 513.0169 2048.0383 2048.0401 1 R.ISFEEFCAVVGGLDIHKK
Calmodulin: 2 peptides; protein score:
29; protein mass: 16,827 Da; peptide
coverage: 22%
1 92 107 28.7 585.6269 1753.859 1753.8635 1 R.VFDKDGNGYISAAELR
2 15 31 23.3 615.6347 1843.8824 1843.884 1 K.EAFSLFDKDGDGTITTK
aFor each peptide identified, the position in protein sequence, Mascot score, experimental and calculated masses, number of trypsin missed cleavage and sequence are indicated.
bFor CaNB (isoform 1), peptide 2 did not meet the score requirements set for our experiment but was considered as a genuine identification after manual validation.
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was performed in a 5 L of plastic container (20 cm diameter) filled
(80% volume) with tap water at 18°C and an Ethovision system (Nol-
dus) for automated video tracking. Recording time was 6 min at a sam-
pling rate of 5 frames per seconds and threshold for immobility at default
settings. Both males and females were used, and each mouse was tested
only once.Groups consisted ofCN279 transgenicmice (n 10) and their
control littermates (mice carrying either no transgene or rtTA2 or tetO-
CAM-AI transgene, n 8), of mixed age and gender: aged (n 4) and
young (n 14), males (n 14) and females (n 4) mice. There was no
statistical influence of age or gender.
Statistics. Data analysis and statistics were performed by using the
GraphPad Prism 5 software. Data on Figures 2, 3, and 4 were analyzed by
one-way ANOVA followed by Newman–Keuls or Dunnett’s tests. The
Mann–Whitney test was used to analyze the data on Figure 6A. Student’s
t test was performed for statistical analysis of behavioral studies.
Results
The SERT C terminus interacts with the
catalytic and regulatory subunits
of calcineurin
The C-terminal domain of SERT fused to
GST (GST-SERT-Ct) was conjugated to
glutathione–Sepharose beads and incu-
bated with detergent-solubilized protein
extracts from mice brain. Control experi-
ments were performed with beads conju-
gated to GST alone. Two-dimensional gel
analysis of proteins retained by affinity re-
vealed that two additional spots (or trains
of spots) were specifically recruited by
GST-SERT Ct (Fig. 1A), compared with
our previous analyses using a peptide
comprising only the 15 C-terminal amino
acids of SERT as bait (Chanrion et al.,
2007). These proteins were identified by
MALDI-TOFmass spectrometry as CaNA
(catalytic subunit, also designated as pro-
tein phosphatase 2B A)  isoform, and
CaNB (regulatory subunit, also desig-
nated as protein phosphatase 2B B) iso-
form 1 (Table 1). Further supporting the
association of CaN with SERT, shotgun
analysis of proteins pulled-down with
GST-SERT Ct by nano-LC-FT-MS/MS
identified both  and  isoforms of CaNA
as well as CaNB isoform 1 (Table 2). No-
tably, calmodulin (CaM), which is known
to tightly associate with CaN heterodimers
(Liu, 2009),was also identified as a potential
partner of SERT by this shotgun approach.
Recruitment of CaN by SERT-Ct was fur-
ther validated by Western blotting using a
polyclonal antibody recognizing both CaN
catalytic and regulatory subunits (Fig. 1B).
Moreover, CaNA was specifically coimmu-
noprecipitated with native SERT expressed
inmice brain (Fig. 1C), indicating that they
form a complex in vivo.
We next generated truncationmutants
of SERT-Ct and fused them to GST to
characterizemore precisely theCaN inter-
action domain within SERT C terminus.
Deletion of the 10N-terminal amino acids
of SERTC terminus almost completely pre-
vented recruitment of CaNA and CaNB,
whereas the deletion of the 24 C-terminal residues did not prevent
association of CaN with SERT-Ct (Fig. 1B), indicating that the 10
N-terminal amino acids of SERT-Ct were necessary and sufficient
for its interaction with CaNA and CaNB. Based on existing similar-
ities between the first five amino acids of this sequence (RLIIT) and
CaNA binding motifs previously described in several proteins
(Aramburu et al., 1998; Li et al., 2007; Takeuchi et al., 2007), we
generated several constructs encoding SERT-Ct with one or several
of these residues mutated into alanine. We found that replacement
of the RLIIT sequence by ALAAA in SERT-Ct abrogated the inter-
action with CaNA and CanB (Fig. 1B), thus identifying the R-IIT
sequenceasacriticalCaNbindingmotif in theSERTCterminus.We
then introduced this modification into the entire SERT sequence
Figure 2. The interaction of SERT with calcineurin depends on calcineurin catalytic activity and Ca 2. A, HEK-293 cells were
transfected with either Flag-tagged CA-CaNA or Flag-tagged PD-CaNA vector, in the absence or presence of Flag-tagged CaNB
vector. Total protein extracts were analyzed by Western blotting using a polyclonal anti-Flag antibody. B, HEK-293 cells were
transfected with NFAT-Luc reporter plasmid in the absence or presence of CA-CaNA ( CaNB) or PD-CaNA ( CaNB) plasmids.
Luciferase activity wasmeasured in cells exposed or not to 10M A23187 for 5min. Data are themean	 SEM of values obtained
in three independent experiments performed in quadruplicate. *p 0.05, **p 0.01. C, D, HEK-293 cells were cotransfected
with plasmids encoding wild-type SERT or SERT mutated on the calcineurin interaction site (SERTCaN) and either CA-CaNA (
CaNB)or PD-CaNA (CaNB)plasmids (C) or cotransfectedwithplasmids encodingSERTandCA-CaNA (CaNB) and treatedornot
with 10M A23187 for 5 min (D). Proteins were immunoprecipitated (IP) with a monoclonal anti-Flag antibody and analyzed by
Western blotting using polyclonal anti-Flag (IP) and anti-GFP (Co-IP) antibodies. Representative blots are shown. Immunoreactive
signals corresponding to SERT coimmunoprecipitated with CaNA were quantified and normalized to the corresponding CaNA
signals in immunoprecipitates. Quantificationdata are themean	SEMof values obtained in three independent experiments.ND,
Not detected. *p 0.05 versus cells expressing SERT and CA-CaNA ( CaNB). §p 0.05 versus cells expressing SERTCaN and
CA-CaNA ( CaNB).
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(SERTCaN) to analyze the role of SERT/
CaN physical interaction in living cells.
Interaction of calcineurin with SERT is
a dynamic process regulated by
calcineurin phosphatase activity and
Ca2
To further characterize SERT/CaN interac-
tion, we transiently expressed in HEK-293
cells SERT in the absence or presence of a
constitutively active CaNA (deleted of the
CaM binding domain, CA-CaNA) or a
phosphatase-dead, dominant-negative CaNA
mutant (PD-CaNA)andofCaNB.Asprevi-
ously observed (Kahl andMeans, 2004), co-
expression of CaNB was required for
expressionofbothCaNAmutants (Fig. 2A).
Therefore, CaNB was systematically coex-
pressed with CA-CaNA or PD-CaNA in
further experiments.We first performed lu-
ciferase assays using the NFAT-Rluc re-
porter gene, to assess CaN activity and to
functionally validate the CaNA constructs.
Exposure of cells to 10 M A23187, a Ca2
ionophore, induced a twofold increase of
basal activity in cells expressingNFAT-Rluc,
which probably reflected activation of en-
dogenous CaN (Fig. 2B). As expected, CA-
CaNA expression elicited a strong luciferase
response, which was not further enhanced
by exposure of cells to A23187. In contrast,
we did not detect any significant increase in
luciferase activity in cells expressing PD-
CaNA (exposed or not to A23187), com-
paredwith cells expressingNFAT-Rluc alone.
We found that SERT was coimmuno-
precipitated with both CA-CaNA and PD-
CaNA (Fig. 2C). However, the amount of
SERT coimmunoprecipitated with PD-
CaNA was much lower than that found in
CA-CaNA immunoprecipitates (Fig. 2C,
lanes 2 and 3), suggesting that CaN activity
promotes association of SERT with CaN.
Consistent with this finding and further
supporting a role of Ca2 in SERT/CaN in-
teraction, treating cellswithA23187 (10M,
5min) increasedcoimmunoprecipitationof
SERT with CA-CaNA (Fig. 2D). As ex-
pected, the mutation of the 596RLIIT600 se-
quence to 596ALAAA600 in theCaNbinding
site of SERT(SERTCaN) strongly reduced
its ability to coimmunoprecipitate with CaN. Moreover, coimmu-
noprecipitation of SERTCaN with CaN was further decreased
when this mutant SERTwas coexpressed with PD-CaNA instead of
CA-CaNA (Fig. 2C).
Calcineurin enhances 5-HT uptake and promotes SERT
localization at the plasmamembrane in HEK-293 cells
Coexpression of CA-CaNA (and CaNB) with SERT in HEK-293
cells induced a marked increase in the velocity of 5-HT uptake,
compared with cells expressing SERT alone (Vmax 6.68	 1.18
vs 3.77 	 0.36 pmol/min, p  0.05; Fig. 3A,C). CA-CaNA ex-
pression did not significantly affect the apparent affinity of SERT
for 5-HT (Km 2.93	 0.47 M in cells coexpressing SERT and
CA-CaNA vs 2.72 	 0.19 M in cells expressing SERT alone).
Coexpression of CA-CaNA (and CaNB) with DAT did not sig-
nificantly modify the velocity of dopamine uptake in HEK-293
cells (Vmax 4.28	 0.66 pmol/min vs 3.35	 0.61 pmol/min in
cells expressing DAT alone, p 0.73; Fig. 3E), although it slightly
but significantly decreased norepinephrine uptake in cells ex-
pressing NET (Vmax  4.66 	 0.15 pmol/min vs 6.94 	 0.21
pmol/min in cells expressing NET alone, p 0.05; Fig. 3F).
In line with the increased 5-HT uptake in cells expressing
CA-CaNA, biotinylation experiments indicated an increase in the
proportion of SERT at the cell surface in cells coexpressing SERT
Figure 3. Calcineurin stimulates 5-HT uptake and promotes SERT localization at the plasmamembrane.A, [ 3H]-5-HT uptake in
HEK-293 cells coexpressing SERT and CA-CaNA or PD-CaNA ( CaNB). B, [ 3H]-5-HT uptake in HEK-293 cells expressing SERT or
SERTCaN in the absence or presence of CA-CaNA ( CaNB). Representative concentration-dependent curves are shown. C, Data
represent the mean	 SEM of Vmax of 5-HT uptake (expressed in percentage of control value measured in cells expressing SERT
alone, 3.77	 0.36 pmol/min) measured in three independent experiments performed on different sets of cultured cells. *p
0.05 versus cells expressing SERT alone. **p  0.01 versus cells expressing SERT alone. n.s., Not significant. D, Cell surface
biotinylation assay performed on HEK-293 cells expressing SERT or SERTCaN in the absence or presence of CA-CaNA ( CaNB).
Total and biotinylated SERT were detected by Western blotting using a monoclonal anti-GFP antibody. Representative blots are
shown. Data, normalized to the amount of total SERT, are the mean	 SEM of densitometric analyses of blots obtained in three
independent experiments. *p 0.05 versus cells expressing SERT. E, [ 3H]-Dopamine uptake in HEK-293 cells coexpressing DAT
and CA-CaNA ( CaNB). F, [ 3H]-Norepinephrine uptake in HEK-293 cells coexpressing NET and CA-CaNA ( CaNB).
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and CA-CaNA, compared with cells expressing SERT alone (Fig.
3D). Coexpression of PD-CaNAwith SERT did not modify max-
imal 5-HT uptake (Vmax 3.89	 0.52 pmol/min, Km 2.24	
0.16 M in cells coexpressing SERT and PD-CaNA; Fig. 3A),
suggesting that CaN-elicited increase of 5-HT uptake was depen-
dent on its phosphatase activity. Moreover, coexpression of CA-
CaNA with SERTCaN did not significantly affect maximal
5-HT uptake (Vmax 3.34	 0.57 pmol/min, Km 2.16	 0.36
M) or SERTCaN plasma membrane expression (Fig. 3B–D).
Notably, maximal 5-HT uptake was significantly decreased in cells
expressing SERTCaN mutant alone (Vmax  2.14 	 0.31 pmol/
min, Km 2.32	 0.63 M), compared with cells expressing SERT
(p  0.01; Fig. 3B,C). This reduced 5-HT uptake via SERTCaN
probably reflects its low ability to interact with endogenously ex-
pressed CaN and thus suggests that SERT
activity can be regulated by endogenous
CaN. Consistent with this hypothesis, si-
lencing CaNA expression in HEK-293 cells
using a small interfering RNA decreased by
32	 6% the maximal velocity of 5-HT up-
take via SERT (p 0.01; Fig. 4A,B).
The calcineurin inhibitor FK506
decreases 5-HT uptake into HEK-293
cells andmesencephalon neurons
Collectively, these results suggested that
bothCaNphosphatase activity and its phys-
ical interactionwith SERTmight contribute
to CaN-elicited enhancement of SERT
transport activity. To further confirm the
role of CaN enzymatic activity in the regu-
lation of SERT transport activity, we then
investigated the effect of the CaN inhibitor
FK506 in HEK-293 cells coexpressing CA-
CaNA and SERT. Using the NFAT lu-
ciferase reporter system, we showed that
FK506 inhibited CaN activity in a
concentration-dependentmanner(pIC50
8.69	 0.24 nM; Fig. 4C) and 5-HT uptake
with a similar apparent affinity (pIC50 
8.26	 0.47 nM; Fig. 4D). Further support-
ing amodulation of SERT transport activity
by endogenous CaN, the CaN inhibitor
decreased 5-HT uptake in HEK-293 cells
expressing SERT alone in the same concen-
tration range (pIC50 8.36	 0.32 nM, Fig.
4E), as well as in mouse mesencephalon
neurons in primary culture (67.0 	 17.1
and 65.3	 9.9% basal uptake, measured
in neurons treated with 10 and 100 nM
FK506, respectively, Fig. 4F).
Calcineurin prevents SERT
phosphorylation and inhibition of 5-
HT uptake induced by a protein kinase
C activator
Several studies have demonstrated that
protein kinaseC (PKC) activation inhibits
5-HT transport activity of SERT in both
recombinant (HEK-293 cells) and native
(platelets, synaptosomes) systems and
that this effect is paralleled by an increase
in SERT phosphorylation (Qian et al.,
1997; Ramamoorthy et al., 1998; Jayanthi et al., 2005; Samuvel et
al., 2005). We thus wondered whether CaN phosphatase activity
could affect PKC-mediated SERT regulation. Consistent with
these previous findings, we found that a pretreatment of HEK-
293 cells expressing SERT alone with the PKC activator
-phorbol 12-myristate 13-acetate (PMA, 100 nM) caused an
50% reduction of 5-HT uptake (Fig. 5A). In contrast, PMA did
not significantly affect 5-HT uptake in cells coexpressing SERT
and CA-CaNA (Fig. 5A), indicating that CaN activity prevents
PKC-induced inhibition of SERT transport activity.
Analysis by nano-LC-FT-MS/MS of SERT phosphorylation
status in HEK-293 cells coexpressing or not CA-CaNA showed
a phosphorylation of SERT at Thr 616 located in the SITPET
sequence of the transporter C terminus (Fig. 5B) and impor-
Figure 4. Silencing calcineurin expression and a pharmacological inhibitor of calcineurin decrease 5-HT uptake via SERT. A, HEK-293
cellsweretransfectedwiththeplasmidencodingSERTandcontrolorCaNAsiRNA.TotalproteinextractswereanalyzedbyWesternblotting
using themonoclonal anti-GFP antibody, the polyclonal anti-CaNA antibody, and the anti-GAPDH antibody.B, [ 3H]-5-HT uptake in HEK-
293 cells expressing SERT in the presence of control or CaNA siRNA. A representative experiment is shown. Data for Vmax of 5-HT uptake,
expressed inpercentageofvalue incells transfectedwithcontrol siRNA(3.78	0.49pmol/min),are themean	SEMofvaluesmeasured
in three independent experiments. **p0.01 versus cells transfectedwith control siRNA.C, Effect of increasing concentrations of FK506
uponNFAT-Luc reporteractivity inHEK-293cells expressingCA-CaNAandCaNB.D,E, Effectof FK506on[ 3H]-5-HTuptake inHEK-293cells
transiently expressingSERTandCA-CaNA(CaNB) (D) or expressingSERTalone (E).Data, expressed inpercentageof valuesmeasured in
theabsenceof FK506, are themean	SEMof triplicatedeterminations obtained in a representative experiment. Twoother independent
experiments performed on different sets of cultured cells yielded similar results. F, Effect of FK506 on [ 3H]-5-HT uptake inmousemesen-
cephalonneurons inprimaryculture.Data,expressed inpercentageofvaluemeasured in theabsenceofFK506(15.8	2.8 fmol/min), are
the mean	 SEM of the results obtained in five independent experiments performed on different sets of cultured neurons. *p 0.05
versus 5-HT uptake in the absence of FK506.
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tant for SERT plasma membrane local-
ization and its uptake function (Ahmed et
al., 2009). However, the relative quantifica-
tionof the corresponding ion signal bymass
spectrometry did not reveal any dephos-
phorylation of this residue in cells express-
ing CA-CaNA. In PMA-treated cells, we
identified an additional phosphorylated
peptide in the N-terminal domain of SERT
(30VVPTPGDKVESGQISNGYSAVPSPGA
GDDTR60; Fig. 5B), and the corresponding
ion signal wasmuch higher in PMA-treated
cells than in cells exposed to vehicle (Fig.
5C). Moreover, expression of CA-CaNA
significantly reduced the phosphorylation
of this peptide in cells treated with PMA,
whereas it did not affect its basal phosphor-
ylation level measured in vehicle-treated
cells (Fig. 5C), indicating that CaN prevents
PKC-elicited SERT phosphorylation. Un-
fortunately, we could not unambiguously
identify byMS/MS the phosphorylated res-
idue of this peptide, which contains several
serines and threonines, as the generated
peptide fragments did not allow us to dis-
criminate between a phosphorylation at
Ser48 or at Ser52 (Fig. 5B).
Calcineurin enhances 5-HT uptake in
mouse brain
To determine whether cerebral 5-HT up-
take via SERT is likewise modulated by
CaN activity, we compared the velocity of
5-HT uptake in synaptosomes from mice
expressing or not CA-CaNA (CN279mice)
or a CaNA auto-inhibitory domain (211
mice) in an inducible manner. Consistent
with the data obtained inHEK-293 cells, in-
duction of CA-CaNA expression by dox in
CN279 mice significantly increased synap-
tosomal 5-HT uptake (Vmax 5.65	 0.37
pmol/min vs 3.95 	 0.11 pmol/min in the
corresponding control mice treated with
dox, p 0.05; Km 0.19	 0.05 vs 0.13	
0.04 M, p  0.210) (Fig. 6A). In line with the increase in 5-HT
transport in CN279 mice, we found that [3H]-citalopram binding
was significantly increased in plasma membrane-enriched fraction
from CN279mice treated with dox (Bmax 784	 58 vs 637	 59
fmol/mg of protein in control mice, p 0.05; Kd 5.78	 0.85 vs
7.21	0.73nM,p0.223) (Fig.6C).Conversely,bothsynaptosomal
5-HT uptake and [3H]-citalopram binding to plasma membrane-
enriched fraction were significantly reduced by induction of the
CaNA auto-inhibitory domain, compared with the corresponding
control mice treated with dox (Vmax of 5-HT uptake 3.58	 0.17
vs5.09	0.39pmol/min incontrolmice,p0.05;Km0.10	0.02
vs 0.12	0.03M,p0.313; Bmax564	44 vs 712	21 fmol/mg
of protein, p 0.05;Kd 3.68	 0.69 vs 3.35	 0.64 nM, p 0.578)
(Fig. 6B,D).
Brain calcineurin expression decreases immobility time in the
forced swim test
Collectively, these results support a role for CaN enzymatic ac-
tivity in the control of cerebral 5-HT uptake. These findings,
together with previous observations indicating an important role
for CaN phosphatase activity in the mechanisms of action of
antidepressants (Crozatier et al., 2007), led us to examine
whether expression of CA-CaNAmodifies behavior in the FST, a
task assessing behavioral despair and used to evaluate the activity
of antidepressants in rodents. We found that dox-treated CN279
mice spent approximately twice less time immobile than litter-
mate controls in the FST, specifically during min 3–5 after their
initial attempt to escape (Fig. 7), indicating antidepressant-like
activity of CaN.
Discussion
The reuptake of 5-HT into presynaptic nerve terminals via SERT
is a critical factor that determines the activity of the serotonergic
system. Over the past years, an increasing number of studies have
pointed the complexityof the cellularmechanismscontrollingSERT
expression, localization, and transport activity.These include several
phosphorylation events driven by various protein kinases and phos-
phatases and association of SERTwith a number of protein partners
Figure 5. Calcineurin prevents 5-HT uptake and SERT phosphorylation induced by a PKC activator. A, [ 3H]-5-HT uptake in
HEK-293 cells expressing SERT alone or coexpressing SERT and CA-CaNA ( CaNB), pretreated or not with 100 nM PMA for 45min.
A representativeexperiment is shown. TheVmaxof 5-HTuptake, expressed inpercentageof valuemeasured in cells expressingSERT
aloneand treatedwithvehicle (4.04	0.67pmol/min), are themean	SEMof valuesmeasured in four independentexperiments
performed on different sets of cultured cells. *p 0.05 versus cells expressing SERT alone and treated with vehicle. **p 0.01
versus cells expressing SERT alone and treated with vehicle. n.s., Not significant. B, Phosphorylated peptides identified in the
sequence of SERT coexpressed with CA-CaNA ( CaNB) in HEK-293 cells treated with PMA. For the peptide located in the SERT N
terminus, the two putative phosphorylated residues (Ser 48 and Ser 52) are underscored. C, Extracted ion chromatograms of the
30VVPTPGDKVESGQISNGYSAVPSPGAGDDTR 60 phosphorylated peptide measured in protein extracts prepared from HEK-293 cells
expressingSERTaloneor coexpressingSERTandCA-CaNA (CaNB), pretreatedornotwith100nMPMA.MS signalwasnormalized
to the signal of its nonphosphorylated counterpart. Mean	 SEM of normalized abundance values (n 4) are represented on the
right panel. ***p 0.001 versus cells expressing SERT alone and treated with vehicle. $$p 0.01 versus cells expressing SERT
alone and treated with PMA.
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(Zhong et al., 2012). Of these, protein phosphatase 2A (catalytic
subunit)was shown to forma complexwith SERT,which is dynam-
ically regulated by 5-HT and PKC-dependent SERT phosphoryla-
tion and governs transporter phosphorylation and trafficking
(Ramamoorthy et al., 1998; Bauman et al., 2000).
Here, we show a physical association of SERT with CaN, a
brain-enriched, Ca2/CaM-activated phosphatase known to
modulate key proteins essential for synaptic transmission and
neuronal excitability (Baumga¨rtel and Mansuy, 2012). Consis-
tent with the heterodimeric nature of CaN, which consists of a
catalytic CaNA subunit tightly associated with a myristoylated,
Ca2-binding regulatory CaNB subunit, we found that SERT C
terminus associates with both CaNA and CaNB. Three isoforms
of CaNA, CaNA, , and  and two isoforms of CaNB, CaNB1,
andCaNB2, have previously been described,whereasCaNA and
CaNB2 are found almost exclusively in the testis (Liu, 2009).
Thus, only CaNA, , and CaNB1 are relevant in the brain. Our
MS/MS analyses clearly identified these three isoforms, sug-
gesting that both CaNA/CaNB1 and CaNA/CaNB1 het-
erodimers can associate with SERT C terminus. In contrast,
our proteomic screen did not identify any catalytic subunit of
protein phosphatase 2A, suggesting that other domains of
SERT are involved in the recruitment of this phosphatase.
Further validating the assembly of SERT/CaN complexes in
vivo, CaNA was specifically coimmunoprecipitated with na-
tive SERT expressed in the adult brain in mice.
Consistent with a tight association of CaN heterodimers with
CaM, this protein was also identified in our shotgun analyses of
SERT-associated complex, although it was not detected by 2-D
gel analysis of proteins pulled down with SERT C terminus. This
might be the result of the acidic nature of this protein, which
makes its resolution and detection in 2-D gels difficult. The pre-
cise architecture of the complex formed by SERT, CaN het-
erodimer, andCaMalso remains to be better defined.However, it
is likely that SERT directly interacts with the CaNA subunit, as we
identified in the proximal region of SERT C terminus a sequence
sharing some similarities with previously identified CaNA bind-
ing motifs in various CaN partners (Aramburu et al., 1998), and
the mutation of this motif almost completely abolished associa-
tion of CaN with SERT.
The Ca2/CaM complex has long been known to modulate
5-HT uptake via SERT (Jayanthi et al., 1994; Yura et al., 1996;
Turetta et al., 2004). More recently, Ciccone et al. (2008) have
shown that Ca2/CaM-dependent kinase II controls the trans-
port stoichiometry of SERT by promoting SERT interaction with
Syntaxin 1A. Here, we identified another mechanism whereby
Ca2/CaM can affect SERT functional status and which relies on
CaN and its physical association with SERT. Interestingly, this
interaction was itself dependent on both CaN phosphatase activ-
ity and cytosolic Ca2. Indeed, coimmunoprecipitation experi-
ments in transfected HEK-293 cells showed that CA-CaNA
bound more efficiently to SERT than a phosphatase-dead CaNA
mutant, and increasing cytosolic Ca2 concentration further in-
creased association ofCA-CaNA to SERT.However, treating cells
expressing CA-CaNA with a Ca2 ionophore did not further
enhance its constitutive phosphatase activity. This suggests that
Ca2 can promote and/or stabilize SERT/CaN interaction by ac-
Figure 6. Calcineurin catalytic activity enhances cerebral 5-HT uptake. A, B, [ 3H]-5-HT uptake in brain synaptosomes from CN279 or 211mice and from their respective littermate control mice
treated with dox for 12 d. Representative dose–response curves obtained in synaptosomes purified from one mouse of each group are shown on the left. Means of Vmax values measured in the
different groups (n5–7miceper condition) are representedon the right.C,D, [ 3H]-Citaloprambindingmeasuredonmembranepreparations frombrain of CN279or211mice and their respective
controls treatedwith dox. Representative dose–response curves obtained inmembrane-enriched fractions fromonemouse of eachgroupare shownon the left.Means of Bmax values (n5–7mice
per condition) are represented on the right. *p 0.05 vs corresponding control. **p 0.01 vs corresponding control.
Figure 7. Calcineurin decreases immobility time in the forced swim test. Cumulative time spent
immobile in CN279 and littermate controlmice treatedwith dox for 12 d before the FST. CN279mice
spent less time immobile overall than controls (n 10 and 8, respectively, p 0.05), specifically
duringmin 3–5after initial attempt to escape. Data aremean	 SEM. *p 0.05.
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tivating CaN and by a CaN-independent mechanism that re-
mains to be elucidated.
Our results, based on a combination of genetic and pharma-
cological approaches, show that CaN catalytic activity enhances
5-HT transport via SERT and prevents the inhibitory action of
PKC upon SERT functional activity. Indeed, the expression
of CA-CaNA increased 5-HTuptake inHEK-293 cells, whichwas
of comparable level in cells treated or not with a PKC activator,
whereas expression of a phosphatase-deadmutant did not signif-
icantly affect the velocity of 5-HT transport.
Induction of expression of CA-CaNA in mice brain likewise
increased the velocity of cerebral 5-HT uptake. Corroborating
these findings and indicating a role of endogenous CaN in the
regulation of SERT activity, both silencing CaNA expression and
pharmacological inhibition of CaN by FK506 decreased 5-HT
transport activity of SERT in vitro, and brain expression of the
CaNA auto-inhibitory domain reduced cerebral 5-HT uptake.
Notably, regulation of 5-HT uptake by CaN phosphatase activity
correlated with its impact on SERT/CaN interaction. Further
supporting a role of SERT/CaN interaction in CaN-elicited SERT
functional activity, we found that mutating the CaN binding site
in the SERT sequence reduced 5-HT transport. However, we
cannot rule out that this mutation also affected SERT function-
ality via a mechanism independent of CaN binding. Finally, in
contrast to the observed enhancement of SERT transport activity
by CaN phosphatase activity, we found that coexpression of CA-
CaNAwithDATdid not affect the velocity of dopamine uptake in
HEK-293 cells whereas it reduced the uptake of norepinephrine
via NET, indicating that CaN differentiallymodulates the activity
of monoamine transporters.
The molecular events underlying regulation of SERT trans-
port function by CaN remain incompletely elucidated. Our data
suggest that itmight result, at least in part, from the ability of CaN
phosphatase activity to modulate SERT plasma membrane ex-
pression. Indeed, expression of CA-CaN produced a concomi-
tant increase in SERT cell surface expression and 5-HT transport,
whereas expression of the CaN auto-inhibitory domain de-
creased both its plasma membrane expression and 5-HT uptake.
In an effort to demonstrate whether SERT itself is a substrate of
CaN, we found that one Ser residue located in SERT N-terminal
domain was phosphorylated upon exposure of cells to PMA and
that expression of CA-CaNA reduced the phosphorylation of this
Ser elicited by this treatment. This suggests that the ability of CaN
to prevent the downregulation of SERT function caused by PKC
activation might result from its capacity to directly dephosphor-
ylate SERT. However, it is unlikely that this phosphorylation
event underlies upregulation of SERT activity induced by CaN in
the absence of PKC activator, as relative quantification of the
corresponding ion signal by mass spectrometry did not reveal
further dephosphorylation of this residue in cells expressing CA-
CaNA and not treated with PMA. Likewise, CaN did not decrease
the phosphorylation level of Thr616 located in the SITPET se-
quence of the transporter C terminus and important for SERT
uptake function (Ahmed et al., 2009), indicating that CaN-
elicited upregulation of SERT activity does not result fromThr616
dephosphorylation.One cannot rule out thatMS/MS analysis did
not identify all phosphorylated residues in the transporter se-
quence, including other sites potentially dephosphorylated by
CaN, or that CaN dephosphorylates other proteins important for
SERT trafficking in and out of the plasma membrane.
Increasing evidence suggests that CaN plays a pivotal role in
the control of mood. Treatment of patients after heart transplan-
tation with CaN inhibitors to prevent graft rejection is often
accompanied by neuropsychiatric complications, such as depres-
sion and anxiety, which can be alleviated by switching the treat-
ment to an mTOR inhibitor (Lang et al., 2009). Systemic
administration of CaN inhibitors likewise induces depression-
and anxiety-like behaviors in mice, an effect reproduced by local
downregulation of CaN in amygdala using short hairpin RNAs
targeting CaNA (Bahi et al., 2009). Corroborating these observa-
tions and indicating antidepressant-like activity of CaN, induc-
tion of CaNA expression in the adult mouse brain (CN279mice)
decreased immobility time in the FST. In contrast, mice consti-
tutively expressing CA-CaNA (CN98mice) show no variation in
immobility time and only increased sensitivity to antidepressant
effects (Crozatier et al., 2007). This difference in depression-like
behavior might reflect adaptive processes in CN98 mice. Con-
versely, decreased CaN activity was observed in rats exposed to
chronic mild test and inhibition of hippocampal CA3 CaN exac-
erbated depressive-like behavior in these rats (Zhu et al., 2011).
Finally, chronic treatment with an SSRI upregulated CaNprotein
expression in the hippocampus andmice that overexpress CaN in
the hippocampus are more sensitive to the behavioral effects of
antidepressants (Crozatier et al., 2007), suggesting that CaN
would be an indirect target of antidepressants contributing to
their effect upon mood.
Little is known about the cellular mechanisms that underlie the
antidepressant-like effects of CaN. Although not expected given the
opposite action of CaN and antidepressants upon 5-HTuptake, our
results suggest that the behavioral effects of CaNmight result froma
modulationof SERTplasmamembranedensity and5-HT transport
activity. This hypothesis is consistentwith previous findings indicat-
ing a decrease in SERT function in some depressed patients (Parsey
et al., 2006a) and a greater risk for depression (associated to a de-
creased SERT expression) in individuals with the short serotonin
transporter allele (Parsey et al., 2006b). They support thenotion that
a depressive state can be associated with decreased SERT density
and/or 5-HT transport and underscore the importance of identify-
ing theconcomitantmolecular, cellular, andneurochemical changes
forabetterunderstandingof themechanisms leading toan increased
risk for depression.
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